KRAS is a gene that encodes one of the several proteins in the epidermal growth factor receptor (EGFR) signaling pathway that is important in the development and progression of cancer. KRAS can harbor oncogenic mutations that yield a constitutively active protein. KRAS mutations have been reported in up to 1.6% of low-grade gliomas and in 1% of glioblastomas. KRAS mutations have not previously reported in ganglioglioma. The predictive and prognostic significance of KRAS mutations in ganglioglioma is unclear and needs to be further studied. Correlation with other clinical and laboratory findings is recommended.